Skip to main content
. 2020 Aug 27;44(5):979–988. doi: 10.1007/s40618-020-01392-5

Table 1.

Characteristics of the study population according to the diagnosis of NAFLD

No NAFLD (n = 20) NAFLD (n = 32) p valueb
Age (years) 42.13 ± 8.7 45.22 ± 10.9 0.35
Gender (F%) 87% 65% 0.03a
BMI (Kg/m2) 43.8 ± 6.1 42.1 ± 5.4 0.37
Waist circumference (cm) 128.1 ± 12.5 127.7 ± 16.1 0.94
PAS (mmHg) 129.2 ± 10.3 126.9 ± 11.8 0.47
PAD (mmHg) 84.2 ± 6.9 84.9 ± 17.4 0.86
AST (IU/l) 20.8 ± 7.8 29 ± 13.7 0.032
ALT (IU/l) 21.9 ± 10.4 41 ± 23.2  < 0.001
GGT (UI/l) 20.16 ± 7.2 30.8 ± 17.7 0.009
Total cholesterol (mg/dl) 204.7 ± 30.6 190.6 ± 29.6 0.15
HDL-C (mg/dl) 48.8 ± 11.3 45.4 ± 10.7 0.34
LDL-C (mg/dl) 131.6 ± 23.1 113.6 ± 26.6 0.03
Triglycerides (mg/dl) 109 ± 39 167.1 ± 74.5 0.006
Total bilirubin (mg/dl) 3.9 ± 6.7 2.25 ± 3.9 0.34
Direct bilirubin (mg/dl) 1.40 ± 2.84 0.92 ± 1.9 0.58
FBG (mg/dl) 96.8 ± 12.9 103.8 ± 23 0.23
HbA1c (%) 5.3 ± 0.3 5.7 ± 0.63 0.05
FBI (IU/mL) 11.9 ± 7 15.3 ± 8.2 0.29
HOMA-IR 2.85 ± 1.5 3.82 ± 2.4 0.24
HOMA-β% 149.6 ± 145.7 169.2 ± 70.5 0.69
FIB-4 0.8 ± 0.25 1.04 ± 0.3 0.039
Steatosis % [median(range)] 3.5 (0.75–5) 60 (30–70)  < 0.001
Steatosis grade (n, 0/1/2/3) 20/0/0/0 0/8/8/16  < 0.001
Lobular inflammation (n, 0/1/2) 8/12/0 14/8/10 0.10
Ballooning (n, 0/1/2) 19/1/0 12/15/5  < 0.001
Fibrosis (F0/F1/F2/F3/F4) 10/10/0/0/0 10/18/3/1/0 0.20

T test applied

aχ2 test applied

bMann–Whitney test applied. Statistical significance is related to the comparison between NAFLD and non-NAFLD sub-groups